Adenosine A2a Receptor Antagonists for Selective CNS Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for central nervous system diseases such as Parkinson's disease and depression lack effective agents with minimal side effects, particularly in addressing motor impairment and cognitive function, and existing therapies for neurodegenerative diseases often cause additional disorders like dystonia and restless leg syndrome.
Innovation Solution
Development of specific adenosine A2a receptor antagonists, represented by a compound formula I, which can be administered alone or in combination with other agents to treat these conditions, improving motor function and reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for central nervous system diseases are used, then motor impairment and cognitive function can be addressed, but side effects increase causing additional disorders like dystonia and restless leg syndrome
Solution Approach 1:
The patent applies local quality by designing a compound that selectively targets A2a receptors in specific brain regions (particularly the basal ganglia) rather than affecting all adenosine receptors throughout the body. This selective action at the specific receptor subtype and location provides therapeutic benefits for motor impairment while minimizing systemic side effects that cause dystonia and restless leg syndrome
Solution Approach 2:
The invention segments the adenosine receptor system by focusing specifically on A2a receptor antagonism rather than broad adenosine modulation. The compound selectively binds to A2a receptors, separating this specific therapeutic action from the effects on other adenosine receptor subtypes (A1, A2b, A3), thereby achieving targeted therapy with reduced off-target side effects
2Reliability
If existing therapies for neurodegenerative diseases are administered, then disease progression can be managed, but additional disorders such as dystonia and restless leg syndrome are induced
Solution Approach 1:
The compound exhibits local quality by concentrating its pharmacological action in the basal ganglia where A2a receptors are densely expressed and involved in motor control. This localized effect manages neurodegenerative disease progression without inducing the extrapyramidal side effects and movement disorders associated with broader therapeutic approaches
3Object-generated harmful factors
If selective A2a receptor antagonists are developed, then side effects are reduced, but therapeutic coverage for multiple CNS conditions is limited
Solution Approach 1:
The patent demonstrates universality by showing that a single A2a receptor antagonist compound can treat multiple distinct central nervous system conditions including Parkinson's disease, depression, cognitive disorders, and movement disorders. The compound's ability to bind selectively to A2a receptors throughout the CNS provides broad therapeutic coverage across different pathologies without requiring multiple different drug mechanisms
Data Source
AI summary
Compounds having the structural formula Ior a pharmaceutically acceptable salt thereof, wherein:X1 and X2 are 1-3 substituents independently selected from the group consisting of H, alkyl, halo, —CF3, —OCF3, alkoxy, —OH and —CN;n is 0, 1 or 2; andR and R1 are H or alkyl;also disclosed is the use of the compounds in the treatment of CNS diseases such as Parkinson's disease, alone or in combination with other agents for treating CNS diseases, pharmaceutical compositions comprising them and kits comprising the components of the combinations.